Interleukin-12 is reduced in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia

Rentzos, M; Paraskevas, GP; Kapaki, E; Nikolaou, C; Zoga, M; Rombos, A; Tsoutsou, A; D, DV

dc.contributor.author	Rentzos, M	en
dc.contributor.author	Paraskevas, GP	en
dc.contributor.author	Kapaki, E	en
dc.contributor.author	Nikolaou, C	en
dc.contributor.author	Zoga, M	en
dc.contributor.author	Rombos, A	en
dc.contributor.author	Tsoutsou, A	en
dc.contributor.author	D, DV	en
dc.date.accessioned	2014-03-01T01:55:34Z
dc.date.available	2014-03-01T01:55:34Z
dc.date.issued	2006	en
dc.identifier.issn	0022-510X	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/27791
dc.subject	IL-12	en
dc.subject	CSF	en
dc.subject	Alzheimer's disease	en
dc.subject	frontotemporal dementia	en
dc.subject	inflammatory reactions	en
dc.subject.classification	Clinical Neurology	en
dc.subject.classification	Neurosciences	en
dc.subject.other	NECROSIS-FACTOR-ALPHA	en
dc.subject.other	CYTOSKELETON PROTEINS	en
dc.subject.other	DIAGNOSTIC-CRITERIA	en
dc.subject.other	TAU-PHOSPHORYLATION	en
dc.subject.other	INTERFERON-GAMMA	en
dc.subject.other	SENILE PLAQUES	en
dc.subject.other	BETA-PROTEIN	en
dc.subject.other	BRAIN	en
dc.subject.other	ASTROCYTES	en
dc.subject.other	EXPRESSION	en
dc.title	Interleukin-12 is reduced in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia	en
heal.type	journalArticle	en
heal.language	English	en
heal.publicationDate	2006	en
heal.abstract	Interleukin-12 is a heterodimeric cytokine produced by activated blood monocytes, macrophages and glial cells. It enhances differentiation and proliferation of T cells and increases production of proinflammatory cytokines, such as lnterferon-gamma and Tumor Necrosis Factor-alpha. There is little information about the involvement of IL-12 in the pathophysiology of Alzheimer's disease (AD) and other tauopathies. Objectives: The objective of our study was to assess the role of IL-12 as a potential marker of immune reactions in patients with AD and frontotemporal dementia (FTD). Patients and methods: We measured by immunoassay cerebrospinal fluid (CSF) IL-12 levels in 19 patients with AD and 7 patients with FTD in comparison with CSF IL-12 levels in 30 patients with non-inflammatory neurological diseases served as neurological control patients (NCTR-L). IL-12 levels were correlated with age, age of disease onset, disease duration, MMSE score, and rate of dementia progression. A 42 and Total tau (tau(T)) levels in CSF were also measured. Results: Patients with AD had significantly lower CSF IL-12 levels compared with NCTRL patients (p < 0.00 1). Patients with FTD had also lower CS F IL-12 levels compared with NCTRL patients (p < 0.05). Age, sex, disease duration and MMSE score did not affect IL-12 levels in any of the groups. In AD a significant positive correlation was noted between IL-12 levels and TT levels (Rs = 0.46, p = 0.048). Conclusions: Our findings may suggest a reduced inflammatory reaction during the course of AD and FTD. A neurotrophic role of IL-12 and other proinflammatory cytokines cannot be excluded. (c) 2006 Elsevier B.V. All rights reserved.	en
heal.publisher	ELSEVIER SCIENCE BV	en
heal.journalName	JOURNAL OF THE NEUROLOGICAL SCIENCES	en
dc.identifier.isi	ISI:000242483700002	en
dc.identifier.volume	249	en
dc.identifier.issue	2	en
dc.identifier.spage	110	en
dc.identifier.epage	114	en